WO1999009967B1 - Cholesterol-lowering therapy - Google Patents
Cholesterol-lowering therapyInfo
- Publication number
- WO1999009967B1 WO1999009967B1 PCT/US1998/017459 US9817459W WO9909967B1 WO 1999009967 B1 WO1999009967 B1 WO 1999009967B1 US 9817459 W US9817459 W US 9817459W WO 9909967 B1 WO9909967 B1 WO 9909967B1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- subject
- treatment
- serum
- prior
- cholesterol
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Methods are described for preventing or reducing the risk of a first occurrence of a cardiovascular event using an HMG-CoA reductase inhibitor alone or in combination with another lipid altering agent. Subjects to be treated are those having an average serum total cholesterol level, an average to mildly elevated serum low-density lipoprotein cholesterol level, and a below average serum high-density lipoprotein cholesterol level, with no history of clinically evident coronary disease.
Claims
AMENDED CLAIMS
[received by the International Bureau on 26 May 1999 (26.05.99); original claim 1 amended; remaining claims unchanged (1 page)]
1. A method for preventing or reducing the risk of a first occurrence of a cardiovascular event comprising administering a prophylactically effective amount of an HMG-CoA reductase inhibitor alone or in combination with another lipid altering agent to a subject having a serum high-density lipoprotein cholesterol level less than or equal to 50 mg/dl prior to treatment and no history of cUnically evident coronary heart disease.
2. The method of Claim 1 wherein the subject has an average level of serum low-density lipoprotein cholesterol prior to treatment.
3. The method of Claim 2 wherein the subject has a low- density lipoprotein cholesterol level less than or equal to 190 mg/dl prior to treatment.
4. The method of Claim 1 wherein the subject has an average level of serum total cholesterol prior to treatment.
5. The method of claim 1 wherein the subject has a serum triglycerides level of less than or equal to 400 mg/dl prior to treatment.
6. The method of claim 1 wherein the subject has a ratio of total cholesterol/HDL-cholesterol of greater than or equal to 4.5.
8. The method of Claim 7 wherein the subject has an average level of serum low-density lipoprotein cholesterol and an average level of serum total cholesterol prior to treatment.
24
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA002300165A CA2300165A1 (en) | 1997-08-26 | 1998-08-21 | Cholesterol-lowering therapy |
| EP98943329A EP1007019A2 (en) | 1997-08-26 | 1998-08-21 | Cholesterol-lowering therapy |
| AU91153/98A AU9115398A (en) | 1997-08-26 | 1998-08-21 | Cholesterol-lowering therapy |
Applications Claiming Priority (10)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US5696697P | 1997-08-26 | 1997-08-26 | |
| US60/056,966 | 1997-08-26 | ||
| US7685998P | 1998-03-05 | 1998-03-05 | |
| US60/076,859 | 1998-03-05 | ||
| US8536098P | 1998-05-13 | 1998-05-13 | |
| US60/085,360 | 1998-05-13 | ||
| GB9814415.7 | 1998-07-03 | ||
| GBGB9814415.7A GB9814415D0 (en) | 1998-07-03 | 1998-07-03 | Cholesterol-lowering therapy |
| GB9815851.2 | 1998-07-21 | ||
| GBGB9815851.2A GB9815851D0 (en) | 1998-07-21 | 1998-07-21 | Cholesterol-lowering therapy |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| WO1999009967A2 WO1999009967A2 (en) | 1999-03-04 |
| WO1999009967A3 WO1999009967A3 (en) | 1999-05-20 |
| WO1999009967B1 true WO1999009967B1 (en) | 1999-07-08 |
Family
ID=27517467
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/US1998/017459 WO1999009967A2 (en) | 1997-08-26 | 1998-08-21 | Cholesterol-lowering therapy |
Country Status (4)
| Country | Link |
|---|---|
| EP (1) | EP1007019A2 (en) |
| AU (1) | AU9115398A (en) |
| CA (1) | CA2300165A1 (en) |
| WO (1) | WO1999009967A2 (en) |
Cited By (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6982251B2 (en) | 2000-12-20 | 2006-01-03 | Schering Corporation | Substituted 2-azetidinones useful as hypocholesterolemic agents |
| US7030106B2 (en) | 2001-01-26 | 2006-04-18 | Schering Corporation | Sterol absorption inhibitor compositions |
| US7053080B2 (en) | 2001-09-21 | 2006-05-30 | Schering Corporation | Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors |
| US7056906B2 (en) | 2001-09-21 | 2006-06-06 | Schering Corporation | Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women |
| US7071181B2 (en) | 2001-01-26 | 2006-07-04 | Schering Corporation | Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors |
| US7132415B2 (en) | 2001-09-21 | 2006-11-07 | Schering Corporation | Methods and therapeutic combinations for the treatment of xanthoma using sterol absorption inhibitors |
| US7192944B2 (en) | 2003-03-07 | 2007-03-20 | Schering Corp. | Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof |
| US7208486B2 (en) | 2003-03-07 | 2007-04-24 | Schering Corporation | Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof |
| US7235543B2 (en) | 2003-03-07 | 2007-06-26 | Schering Corporation | Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof |
| US7368469B2 (en) | 1999-08-30 | 2008-05-06 | Sanofi-Aventis Deutschland Gmbh | Use of inhibitors of the renin-angiotensin system in the prevention of cardiovascular events |
| US7417039B2 (en) | 2001-01-26 | 2008-08-26 | Schering Corporation | Use of substituted azetidinone compounds for the treatment of sitosterolemia |
| US7459442B2 (en) | 2003-03-07 | 2008-12-02 | Schering Corporation | Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof |
| US7560449B2 (en) | 2002-11-06 | 2009-07-14 | Schering Corporation | Methods and therapeutic combinations for the treatment of demyelination |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2042526A1 (en) * | 1990-06-11 | 1991-12-12 | Adeoye Y. Olukotun | Method for preventing a second heart attack employing an hmg coa reductase inhibitor |
| US5622985A (en) * | 1990-06-11 | 1997-04-22 | Bristol-Myers Squibb Company | Method for preventing a second heart attack employing an HMG CoA reductase inhibitor |
| CA2070149A1 (en) * | 1991-06-04 | 1992-12-05 | Stephen J. Boccuzzi | Hmg-coa reductase inhibitors in the prevention of restenosis following coronary angloplasty |
| US6369103B1 (en) * | 1994-01-18 | 2002-04-09 | Bristol-Myers Squibb Company | Method for preventing or reducing risk of onset of cardiovascular events employing an HMG CoA reductase inhibitor |
-
1998
- 1998-08-21 AU AU91153/98A patent/AU9115398A/en not_active Abandoned
- 1998-08-21 CA CA002300165A patent/CA2300165A1/en not_active Abandoned
- 1998-08-21 EP EP98943329A patent/EP1007019A2/en not_active Withdrawn
- 1998-08-21 WO PCT/US1998/017459 patent/WO1999009967A2/en not_active Application Discontinuation
Cited By (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7368469B2 (en) | 1999-08-30 | 2008-05-06 | Sanofi-Aventis Deutschland Gmbh | Use of inhibitors of the renin-angiotensin system in the prevention of cardiovascular events |
| US6982251B2 (en) | 2000-12-20 | 2006-01-03 | Schering Corporation | Substituted 2-azetidinones useful as hypocholesterolemic agents |
| US7030106B2 (en) | 2001-01-26 | 2006-04-18 | Schering Corporation | Sterol absorption inhibitor compositions |
| US7071181B2 (en) | 2001-01-26 | 2006-07-04 | Schering Corporation | Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors |
| US7612058B2 (en) | 2001-01-26 | 2009-11-03 | Schering Corporation | Methods for inhibiting sterol absorption |
| US7417039B2 (en) | 2001-01-26 | 2008-08-26 | Schering Corporation | Use of substituted azetidinone compounds for the treatment of sitosterolemia |
| US7053080B2 (en) | 2001-09-21 | 2006-05-30 | Schering Corporation | Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors |
| US7056906B2 (en) | 2001-09-21 | 2006-06-06 | Schering Corporation | Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women |
| US7132415B2 (en) | 2001-09-21 | 2006-11-07 | Schering Corporation | Methods and therapeutic combinations for the treatment of xanthoma using sterol absorption inhibitors |
| US7560449B2 (en) | 2002-11-06 | 2009-07-14 | Schering Corporation | Methods and therapeutic combinations for the treatment of demyelination |
| US7235543B2 (en) | 2003-03-07 | 2007-06-26 | Schering Corporation | Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof |
| US7368563B2 (en) | 2003-03-07 | 2008-05-06 | Schering Corporation | Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof |
| US7378518B2 (en) | 2003-03-07 | 2008-05-27 | Schering Corporation | Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof |
| US7368562B2 (en) | 2003-03-07 | 2008-05-06 | Schering Corporation | Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof |
| US7459442B2 (en) | 2003-03-07 | 2008-12-02 | Schering Corporation | Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof |
| US7208486B2 (en) | 2003-03-07 | 2007-04-24 | Schering Corporation | Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof |
| US7192944B2 (en) | 2003-03-07 | 2007-03-20 | Schering Corp. | Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CA2300165A1 (en) | 1999-03-04 |
| WO1999009967A3 (en) | 1999-05-20 |
| EP1007019A2 (en) | 2000-06-14 |
| AU9115398A (en) | 1999-03-16 |
| WO1999009967A2 (en) | 1999-03-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO1999009967B1 (en) | Cholesterol-lowering therapy | |
| AU5074196A (en) | Method for preventing a second heart attack employing an HMG CoA reductase inhibitor | |
| Walker | Simvastatin: the clinical profile | |
| CA2088254A1 (en) | Treatment for hypercholesterolemia | |
| BR0013704A (en) | Use of inhibitors of the renin-angiotensin system in the prevention of cardiovascular cases | |
| CA2164291A1 (en) | Methods and pharmaceutical compositions useful for treating neurological disorders | |
| WO1999066031A3 (en) | Pharmaceutical factor vii preparation | |
| WO1999018952B1 (en) | UPREGULATION OF TYPE III ENDOTHELIAL CELL NITRIC OXIDE SYNTHASE BY HMG-CoA REDUCTASE INHIBITORS | |
| CA2238098A1 (en) | Use of nadph oxidase inhibitors for the manufacture of a medicament for prevention of atherosclerosis | |
| CA2142314A1 (en) | Method of Reducing Blood Levels of Total Cholesterol and Low-Density Lipoprotein Cholesterol | |
| WO2001089554A3 (en) | Treatment of acute coronary syndrome with glp-1 | |
| WO2000069445A8 (en) | Combination therapy for treating hypercholesterolemia | |
| CA2248032A1 (en) | Serum cholesterol lowering agent | |
| WO1998001100A3 (en) | Method for treating homozygous familial hypercholesterolemia | |
| WO2002000210A3 (en) | Use of agents capable of reducing uric acid levels for the treatment of cardiovascular disease | |
| WO2002072104A3 (en) | Antihypertensive agent and cholesterol absorption inhibitor combination therapy | |
| EP1634605A3 (en) | treatment of dyslipidemia in a patient having type 2 diabetes | |
| WO1996001253A3 (en) | PLA2 inhibitors and their use for inhibition of intestinal cholesterol absorption | |
| WO2000066068A3 (en) | Method for inducing growth and enhancing survival of nervous tissue | |
| CA2253130A1 (en) | A medicament for treating obesity and improving lipid metabolism | |
| WO2001032160A3 (en) | Modification of cholesterol concentrations with citrus phytochemicals | |
| Rengo et al. | Activity of lercanidipine in double-blind comparison with nitrendipine in combination treatment of patients with resistant essential hypertension | |
| AU5544994A (en) | Use of 17alpha-dihydroequilenin for lowering cholesterol | |
| Schlueter et al. | Metabolic effects of converting enzyme inhibitors: focus on the reduction of cholesterol and lipoprotein (a) by fosinopril | |
| Leon et al. | Blood Lipid Effects of Antihypertensive Therapy: A Double‐Blind Comparison of the Effects of Methyldopa and Propranolol |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A2 Designated state(s): AL AM AU AZ BA BB BG BR BY CA CN CU CZ EE GE HR HU ID IL IS JP KG KR KZ LC LK LR LT LV MD MG MK MN MX NO NZ PL RO RU SG SI SK SL TJ TM TR TT UA US UZ VN YU |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
| AK | Designated states |
Kind code of ref document: A3 Designated state(s): AL AM AU AZ BA BB BG BR BY CA CN CU CZ EE GE HR HU ID IL IS JP KG KR KZ LC LK LR LT LV MD MG MK MN MX NO NZ PL RO RU SG SI SK SL TJ TM TR TT UA US UZ VN YU |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
| DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| AK | Designated states |
Kind code of ref document: B1 Designated state(s): AL AM AU AZ BA BB BG BR BY CA CN CU CZ EE GE HR HU ID IL IS JP KG KR KZ LC LK LR LT LV MD MG MK MN MX NO NZ PL RO RU SG SI SK SL TJ TM TR TT UA US UZ VN YU |
|
| AL | Designated countries for regional patents |
Kind code of ref document: B1 Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
| ENP | Entry into the national phase in: |
Ref country code: CA Ref document number: 2300165 Kind code of ref document: A Format of ref document f/p: F Ref document number: 2300165 Country of ref document: CA |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 1998943329 Country of ref document: EP |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 91153/98 Country of ref document: AU |
|
| WWP | Wipo information: published in national office |
Ref document number: 1998943329 Country of ref document: EP |
|
| WWW | Wipo information: withdrawn in national office |
Ref document number: 1998943329 Country of ref document: EP |